Inflachromene manufacturers
- Inflachromene
-
- $117.00
-
2026-09-10
- CAS:908568-01-4
- Purity: 99.39%
- Supply Ability: 10g
|
| | Inflachromene Basic information |
| Product Name: | Inflachromene | | Synonyms: | Inflachromene;Inflachromene
(ICM);5,12b-dihydro-10-hydroxy-7,7-dimethyl-2-phenyl-1H,7H-[1]benzopyrano[4,3-c][1,2,4]triazolo[1,2-a]pyridazine-1,3(2H)-dione;1H,7H-[1]Benzopyrano[4,3-c][1,2,4]triazolo[1,2-a]pyridazine-1,3(2H)-dione, 5,12b-dihydro-10-hydroxy-7,7-dimethyl-2-phenyl-;5-hydroxy-9,9-dimethyl-15-phenyl-8-oxa-13,15,17-triazatetracyclo[8.7.0.02,7.013,17]heptadeca-2(7),3,5,10-tetraene-14,16-dione;ICM | | CAS: | 908568-01-4 | | MF: | C21H19N3O4 | | MW: | 377.39 | | EINECS: | | | Product Categories: | | | Mol File: | 908568-01-4.mol |  |
| | Inflachromene Chemical Properties |
| Boiling point | 532.6±60.0 °C(Predicted) | | density | 1.50±0.1 g/cm3(Predicted) | | storage temp. | Store at -20°C | | solubility | DMF:30.0(Max Conc. mg/mL);79.49(Max Conc. mM)
DMSO:30.0(Max Conc. mg/mL);79.49(Max Conc. mM)
DMSO:PBS (pH 7.2) (1:4):0.2(Max Conc. mg/mL);0.53(Max Conc. mM)
Ethanol:2.5(Max Conc. mg/mL);6.62(Max Conc. mM) | | form | A crystalline solid | | pka | 9.65±0.40(Predicted) | | color | White to yellow |
| | Inflachromene Usage And Synthesis |
| Uses | Inflachromene is a novel microglial inhibitor, which binds to HMGB1 (High Mobility Group Box 1) and HMGB2 (High mobility Group Box 2) inhibiting microglia-mediated neuroinflammation. | | in vivo | Inflachromene (2-10 mg/kg; i.p. once daily for 4 days) effectively blocks LPS-mediated microglial activation[2].
Inflachromene (10 mg/kg; i.p. once daily for 30 days) significantly reduces the progression of disease, as determined by EAE clinical score[2].
Inflachromene (1 mg/kg; i.v.) exhibits long half-life (14.1±6.43 h) and moderate Vss (2.02±1.02 L/kg)[1].
Inflachromene (1 mg/kg; p.o.) exhibits high oral bioavailability (94%) and Cmax (0.59±0.16 g/mL)[1]. | Animal Model: | Male C57BL/6 mice (11 weeks; 25-30 g) are treated with LPS[2] | | Dosage: | 2, 10 mg/kg | | Administration: | I.p. once daily for 4 days | | Result: | Blocked LPS-mediated microglial activation, even at a dose of 2 mg/kg. |
| Animal Model: | Sprague-Dawley (SD) rats (7 weeks; 230-250 g)[1] | | Dosage: | 1 mg/kg (Pharmacokinetic Analysis) | | Administration: | I.v. and p.o. administration | | Result: | I.v.: t1/2=14.1±6.43 h; CL= 0.14±0.01 L/kg/h; Vss=2.02±1.02 L/kg.
P.o.: t1/2=7.96±1.16 h; F=94%; Cmax=0.59±0.16 g/mL.
|
|
| | Inflachromene Preparation Products And Raw materials |
|